PT-141 (Bremelanotide) Safety in Adults 65 and Older: What the Evidence Shows

HealthRX.com

Bremelanotide safety in adults 65 and older is not established

Print or save as PDF

Key numbers

  • 6 mmHgMaximal systolic blood pressure rise after one dose in clinical studies, premenopausal trial womenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Nausea rate on Vyleesi versus placebo in pooled phase 3 trials of premenopausal womenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 18%Share of women on Vyleesi who stopped treatment for an adverse reaction, versus 2% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Bremelanotide

  • Geriatric labeling / Safety and effectiveness not established in geriatric patients [1]
  • Approved use / Premenopausal women with acquired, generalized HSDD; not for postmenopausal women or men [1]
  • Trial population / 1,247 women in the safety pool, ages 19 to 56, mean age 39 [1]
  • Dose / 1.75 mg subcutaneously at least 45 minutes before activity, one dose per 24 hours, up to 8 per month [1]
  • Blood pressure / Maximal rise 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, baseline within 12 hours [1]
  • Contraindications / Uncontrolled hypertension or known cardiovascular disease [1]
  • Kidney / No adjustment for eGFR 30 to 89 mL/min/1.73 m2; use with caution below 30 [1]
  • Liver / No adjustment for Child-Pugh A or B; not evaluated in severe impairment [1]

What does the label say about adults 65 and older?

The Vyleesi prescribing information answers it in one line: 'The safety and effectiveness of VYLEESI have not been established in geriatric patients' [1].

That section is being revised. FDA approved a labeling supplement on October 22, 2026 that updates Section 8 (Use in Specific Populations) and the patient information; the revised text was not yet in DailyMed on October 28, 2026 [1][3].

The indication also limits who the drug is for. Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and the label states it is not indicated for HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance [1]. A woman past menopause falls outside the labeled population, as does a man of any age [1]. Products sold as compounded or research-use PT-141 are not Vyleesi and are not FDA-approved drugs [8].

Questions worth asking

Choose the questions you want to keep

Who was actually studied?

The two identical phase 3 trials, known as RECONNECT, were 24-week randomized, double-blind, placebo-controlled studies in premenopausal women with acquired, generalized HSDD [1][2]. Of 1,267 women randomized, 1,247 made up the safety population and 1,202 the efficacy population [2]. The enrolled age range was 19 to 56, with a mean age of 39; 86% of participants were White and 12% were Black [1]. Because the range stopped at 56, the trials did not include adults 65 and older.

A 52-week open-label extension followed: of 856 women who completed the core phase, 684 enrolled and 272 completed, with all analyses descriptive and no placebo group [4].

Blood pressure: the maximal and mean numbers are different

Each dose transiently raises blood pressure and lowers heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. Those are maximal figures, not averages, and repeat daily dosing 24 hours apart for up to 16 days produced no additive effect [1].

A separate open-label ambulatory monitoring study of 127 premenopausal women dosed once daily for 8 days found mean daytime increases of 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1].

The label's instructions around this are specific. It says to consider the patient's cardiovascular risk before starting and periodically during treatment and to make sure blood pressure is well controlled; the drug is not recommended for patients at high risk for cardiovascular disease and is contraindicated in uncontrolled hypertension or known cardiovascular disease [1].

Kidney and liver function

Exposure to bremelanotide rises with organ impairment: about 1.5-fold in moderate and 2-fold in severe renal impairment, and 1.2-fold in mild to 1.7-fold in moderate hepatic impairment. The mean terminal half-life after the approved dose is about 2.7 hours [1].

The label's guidance is narrower than 'avoid in kidney disease.' No dose adjustment is recommended for mild to moderate renal impairment, defined as eGFR 30 to 89 mL/min/1.73 m2; in severe impairment (eGFR below 30) it says to use Vyleesi with caution because those patients may have an increase in the incidence and severity of adverse reactions such as nausea and vomiting [1]. For the liver, no adjustment is recommended for Child-Pugh A or B, and the drug has not been evaluated in severe hepatic impairment [1].

Side effects: the rates from the trials

In the pooled phase 3 trials (Vyleesi 627 women, placebo 620), the common adverse reactions were nausea 40.0% versus 1.3%, flushing 20.3% versus 0.3%, injection site reactions 13.2% versus 8.4%, headache 11.3% versus 1.9%, vomiting 4.8% versus 0.2%, and dizziness 2.2% versus 0.5% [1]. Serious adverse reactions occurred in 1.1% on Vyleesi versus 0.5% on placebo, and 18% versus 2% stopped treatment because of an adverse reaction, most often nausea (8%) [1].

Nausea had a median onset within one hour and lasted about two hours; it was highest after the first dose (21% of patients) and fell to about 3% with later doses [1]. Pre-treating with oral ondansetron 8 mg 30 minutes before a dose did not reduce nausea in a phase 4 study of 228 healthy women and is not recommended; treating nausea after the dose has not been formally studied [1]. Focal hyperpigmentation, including the face, gums and breasts, was reported by 1% of patients taking up to 8 doses a month versus none on placebo, with higher risk in darker skin and with daily dosing [1].

These rates come from the pooled phase 3 trials in premenopausal women aged 19 to 56 [1].

Drug interactions in the label

Bremelanotide may significantly decrease the systemic exposure of oral naltrexone, and the label says to avoid using Vyleesi with oral naltrexone-containing products intended to treat alcohol or opioid addiction because of the severe consequence of naltrexone treatment failure [1]. It may also slow gastric emptying, so the label says to avoid Vyleesi when taking oral drugs that depend on threshold concentrations for efficacy, such as antibiotics, and to consider skipping it when a quick oral effect is wanted, such as with indomethacin [1]. In clinical pharmacology studies, only naltrexone and indomethacin were meaningfully affected [1].

Alcohol was tested directly: in a crossover study of 24 healthy volunteers, alcohol at 0.6 g/kg did not change bremelanotide blood levels, and flushing and headache rates with the combination were similar to the higher of the two single-agent rates (that study used a 20 mg intranasal dose, about 2.5-fold the Cmax of Vyleesi) [1].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, what does each bremelanotide dose do to blood pressure?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Is Vyleesi approved for women over 65?
The label sets no chronological age cutoff, but Vyleesi is indicated only for premenopausal women with acquired, generalized HSDD. It is not indicated for postmenopausal women, and its safety and effectiveness have not been established in geriatric patients [1]. The trials enrolled women aged 19 to 56, mean age 39 [1].
How much does bremelanotide raise blood pressure?
In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose and usually returning to baseline within 12 hours, with heart rate falling up to 5 beats per minute [1]. In an ambulatory study of 127 premenopausal women dosed daily for 8 days, mean daytime increases were 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. The phase 3 trials did not include adults 65 and older [1].
Can people with kidney disease use bremelanotide?
The label recommends no dose adjustment for eGFR 30 to 89 mL/min/1.73 m2 and says to use it with caution below 30, where nausea and vomiting may be more frequent or severe [1]. Exposure is about 1.5-fold higher in moderate and 2-fold higher in severe renal impairment [1].
What interacts with bremelanotide?
The label says to avoid it with oral naltrexone products used for alcohol or opioid addiction, because bremelanotide may significantly lower naltrexone exposure [1]. It may slow stomach emptying, so the label says to avoid it with oral drugs that depend on threshold concentrations, such as antibiotics, and to consider skipping a dose when a fast oral effect is wanted, such as with indomethacin [1].
Is dizziness a concern in older adults taking PT-141?
Dizziness was reported by 2.2% of women on bremelanotide versus 0.5% on placebo in the phase 3 trials, which enrolled premenopausal women aged 19 to 56, so these figures do not describe older adults [1].
What does the label say to monitor?
It says to consider the patient's cardiovascular risk before starting and periodically during treatment and to ensure blood pressure is well controlled [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease and is not recommended for patients at high risk for cardiovascular disease [1].
Show all 8 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
  3. U.S. Food and Drug Administration.
  4. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917.
  5. High Blood Pressure Facts | High Blood Pressure | CDC.
  6. Chapter 1: Definition and classification of CKD - PMC.
  7. U.S. Food and Drug Administration.
  8. Official web page.
PT-141 geriatric safety: evidence summary chart
Image: HealthRX.com. Full PT-141 geriatric safety guide and sources at healthrx.com/pt-141.